{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:44:57Z","timestamp":1773161097182,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZSM201801060"],"award-info":[{"award-number":["SZSM201801060"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jdiacomp.2025.109174","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:29:40Z","timestamp":1757514580000},"page":"109174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A comparative analysis of cost-utility: Chiglitazar vs. sitagliptin in patients with type 2 diabetes in China"],"prefix":"10.1016","volume":"39","author":[{"given":"Zeyu","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoru","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guimei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiling","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.109174_bb0005","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0010","series-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2025"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0015","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.4239\/wjd.v14.i10.1573","article-title":"Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: a meta-analysis","volume":"14","author":"Lin","year":"2023","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0020","first-page":"16","article-title":"Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition)","volume":"17","author":"Chinese Diabetes Society","year":"2025","journal-title":"Chin J Diabetes Mellitus"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0025","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.scib.2021.02.027","article-title":"Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)","volume":"66","author":"Jia","year":"2021","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0030","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","article-title":"UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30\u00a0year United Kingdom Prospective Diabetes Study: UKPDS 82","volume":"56","author":"Hayes","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0035","first-page":"72","article-title":"The world health report","volume":"19","author":"World Health Organization","year":"2002","journal-title":"Midwifery"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0040","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1017\/S0266462312000608","article-title":"Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China","volume":"28","author":"Gao","year":"2012","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0045","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/jdi.12905","article-title":"Direct medical costs for patients with type 2 diabetes in 16 tertiary hospitals in urban China: a multicenter prospective cohort study","volume":"10","author":"Li","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0050","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s13300-019-00683-2","article-title":"Meta-analysis and cost-effectiveness analysis of insulin glargine 100\u00a0U\/mL versus insulin Degludec for the treatment of type 2 diabetes in China","volume":"10","author":"Su","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0055","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3111\/13696998.2015.1067622","article-title":"Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies","volume":"18","author":"Deng","year":"2015","journal-title":"J Med Econ"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0060","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/13696998.2019.1570220","article-title":"Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes","volume":"22","author":"Cai","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0065","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3389\/fphar.2019.00480","article-title":"Cost-effectiveness of canagliflozin versus dapagliflozin added to metformin in patients with type 2 diabetes in China","volume":"10","author":"Hou","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0070","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/1753-0407.12612","article-title":"Cost-effectiveness of prevention and management of diabetic foot ulcer and amputation in a health resource-limited setting","volume":"10","author":"Wu","year":"2018","journal-title":"J Diabetes"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0075","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/0272989X15606903","article-title":"Valuing health-related quality of life in type 2 diabetes patients in China","volume":"36","author":"Pan","year":"2016","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1524-4733.2005.00046.x","article-title":"The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects","volume":"8","author":"Currie","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0085","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/027298902400448902","article-title":"Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)","volume":"22","author":"Clarke","year":"2002","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0090","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost-effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0095","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0100","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1111\/dom.15973","article-title":"Cost-utility analysis and drug pricing of once-weekly insulin icodec versus once-daily insulin degludec for type 2 diabetes patients treated with basal insulin in China","volume":"26","author":"Hu","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/dom.16031","article-title":"Cost-utility analysis of once-weekly insulin icodec and once-daily insulin glargine in patients with type 2 diabetes receiving basal-bolus insulin therapy in China","volume":"27","author":"Dai","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0110","first-page":"718","article-title":"Cost-utility analysis of 5 kinds of GLP-1RAs in the treatment of poorly controlled type 2 diabetes mellitus treated with metformin","volume":"35","author":"Xie","year":"2024","journal-title":"China Pharm"},{"key":"10.1016\/j.jdiacomp.2025.109174_bb0115","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40273-024-01398-4","article-title":"Estimating risk factor time paths among people with type 2 diabetes and QALY gains from risk factor management","volume":"42","author":"Gao","year":"2024","journal-title":"Pharmacoeconomics"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:04:06Z","timestamp":1773101046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725002272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1056872725002272"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109174","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative analysis of cost-utility: Chiglitazar vs. sitagliptin in patients with type 2 diabetes in China","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109174"}}